Piezo gene expression level enhancer

A screening method using Piezo gene expression as an index identifies components to enhance Piezo gene expression, improving facial structure and mechanical function by strengthening tendons and enhancing stimulus responsiveness of tendon cells, addressing age-related deterioration.

JP2024159331APending Publication Date: 2024-11-08POLA CHEMICAL INDUSTRIES INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023075263
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-28
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing technologies fail to address age-related changes in facial structure and mechanical function by focusing on the relationship between the Piezo gene expression level and tendon structure deterioration.

Method used

A method is developed to screen for components that enhance Piezo gene expression, using the Piezo gene expression level as an index, and includes ingredients like Geranium robertianum L., Sanguisorba officinalis, and royal jelly to increase Piezo gene expression, thereby improving tendon structure and mechanical function.

Benefits of technology

The method effectively increases Piezo gene expression, leading to improved facial structure and mechanical function by strengthening tendons and enhancing stimulus responsiveness of tendon cells, thus reversing age-related deterioration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024159331000001
    Figure 2024159331000001
  • Figure 2024159331000002
    Figure 2024159331000002
  • Figure 2024159331000003
    Figure 2024159331000003
Patent Text Reader

Abstract

To provide a novel screening method for components that improve facial changes associated with aging, and also to provide a novel agent for enhancing the Piezo expression level, and a novel agent for improving facial changes associated with aging.SOLUTION: A screening method is provided that involves selecting components for improving changes in facial structure and / or mechanical function associated with aging, with reference to the expression level of the Piezo gene in cells. An agent for use in enhancing the expression level of Piezo gene is also provided, comprising one or more components selected from the group consisting of Geranium robertianum L. extract, Mulberry bark extract, Sanguisorba officinalis extract, and royal jelly as an active ingredient.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for screening for an agent that enhances the expression level of the Piezo gene and for a component that improves the associated age-related changes in facial structure and / or mechanical function. [Background technology]

[0002] Piezo proteins are channel proteins that exist on cell membranes and function as sensors for sensing touch, hearing, balance, etc. There are two Piezo genes, Piezo1 and Piezo2. Here, it has been previously known that a transcription factor called Mohawk (Mkx) is involved in the function of tendon cells in subcutaneous tissue (see Non-Patent Document 1). Furthermore, it is known that increasing the expression level of Piezo specifically in tendons increases Mkx, and that the expression of Piezo maintains tendon function (see Non-Patent Document 2).

[0003] Incidentally, sagging skin and wrinkles that become more noticeable with age are thought to be caused in part by changes in the structure of the subcutaneous tissue in the face.

[0004] A technique for improving sagging skin and wrinkles is known that improves a mesh-like fibrous structure called the retinaculum cutis, which exists in subcutaneous tissue. Patent Document 1 describes a skin retinaculum improving agent that has the effect of increasing the expression level of a protein that is a skin retinaculum component in cells.

[0005] In addition, a method is known for screening components that improve sagging, using as an indicator cells that express components of subcutaneous tissue that decrease with age. Patent Document 2 describes a method for screening candidate substances that improve subcutaneous tissue structure, using the expression levels of components that constitute the cutaneous retinaculum as an index. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Patent No. 7190248 [Patent Document 2] Patent No. 6993076 [Non-patent literature]

[0007] [Non-Patent Document 1] Mol Cell Biol. 2016 Mar 31;36(8):1297-309. [Non-Patent Document 2] Nakamichi et al., Sci. Transl. Med. 14, eabj5557 (2022) 1 June 2022. Summary of the Invention [Problem to be solved by the invention]

[0008] As mentioned above, various techniques have been developed to improve facial changes due to aging. However, there was no technology that focused on the relationship between age-related changes in the face and the expression level of the Piezo gene. As mentioned above, the relationship between the Piezo gene and the tendon structure in the subcutaneous tissue was known. However, there was no technology that could improve facial changes by increasing the expression level of the Piezo gene to bring the tendon structure, which has deteriorated with age, closer to a young state. In view of the above circumstances, the present invention provides a novel method for screening components that improve facial changes associated with aging. Another objective of the present invention is to provide an agent that enhances the expression level of a novel Piezo gene. Another objective of the present invention is to provide a novel agent for improving facial changes due to aging. [Means for solving the problem]

[0009] The expression level of Mkx is increased by increasing the expression level of the Piezo gene. Furthermore, the increase in the expression level of Mkx improves tendon structure. As a result of intensive research, the present inventors have found for the first time that the expression level of the Piezo gene decreases with age. This discovery led to the discovery that the decrease in the expression level of the Piezo gene with age is a factor in the deterioration of tendon structure with age, and in turn, in changes in facial structure and mechanical function. This finding has made it clear that a component having the effect of increasing the expression level of the Piezo gene can improve changes in facial structure and mechanical function associated with age.

[0010] That is, the present invention, which solves the above-mentioned problems, is a screening method comprising selecting a component that improves age-related changes in facial structure and / or changes in facial mechanical function using the expression level of the Piezo gene in cells as an indicator.

[0011] In a preferred form of the invention, the age-related changes to the face are due to age-related deterioration of facial tendons or structures supported by the tendons.

[0012] In a preferred embodiment of the present invention, the age-related facial changes are at least one selected from the group consisting of facial sagging, facial wrinkles, facial surface irregularities, and reduced skin elasticity.

[0013] Furthermore, based on the above-mentioned discovery that the expression level of the Piezo gene decreases with age, the present inventors have completed the following invention. That is, the present invention, which solves the above-mentioned problems, also relates to a screening method, which includes selecting a component used to ameliorate the age-related decrease in the expression level of the Piezo gene, using the expression level of the Piezo gene in cells as an indicator.

[0014] It is also known that tendon cells respond to stimuli by increasing the expression level of the Piezo gene. As a result of intensive research, the present inventors have found that the expression level of the Piezo gene in response to stimuli in tendon cells decreases with age. Based on this finding, the present inventors have completed the following invention. In other words, the present invention, which solves the above-mentioned problems, also relates to a screening method, which includes selecting a component that improves the age-related decrease in stimulus responsiveness of tendon cells using the expression level of the Piezo gene in cells as an indicator.

[0015] A preferred embodiment of the present invention is the above-described screening method, characterized in that the expression level of the Piezo gene in tendon cells is used as an index.

[0016] Furthermore, as a result of extensive research, the present inventors have discovered an extract that is effective in enhancing the expression level of the Piezo gene, and have thus completed the present invention. That is, the present invention, which solves the above-mentioned problems, also relates to an agent used for enhancing the expression level of the Piezo gene, comprising one or more active ingredients selected from the group consisting of an extract of Geranium robertianum L., an extract of Sophora umbellata, an extract of Sanguisorba officinalis, and royal jelly.

[0017] A preferred embodiment of the present invention is used to enhance the expression level of the Piezo gene in tendon cells.

[0018] A preferred form of the invention is used to improve age-related changes in facial structure and / or mechanical function.

[0019] Based on the new discovery that facial changes associated with aging can be improved by increasing the expression level of the Piezo gene, the present invention has been completed. In other words, the present invention, which solves the above-mentioned problems, also relates to an agent used to improve age-related changes in facial structure and / or changes in facial mechanical function, comprising as active ingredients one or more ingredients selected from the group consisting of extracts of Geranium robertianum L., Sophora japonica, Sanguisorba officinalis, and royal jelly.

[0020] In a preferred form of the invention, said age-related changes to the face are due to age-related deterioration of the facial tendons, or structures supported by the tendons.

[0021] In a preferred embodiment of the present invention, the age-related facial changes are at least one selected from the group consisting of facial sagging, facial wrinkles, facial surface irregularities, and reduced skin elasticity.

[0022] A preferred embodiment of the present invention is used to improve the decline in responsiveness of tendon cells to stimuli that occurs with aging.

[0023] Furthermore, based on the new discovery that the age-related decrease in the responsiveness of tendon cells to stimuli can be improved by increasing the expression level of the Piezo gene, the present inventors have completed the present invention as described below. Specifically, the present invention also relates to an agent used for improving the decline in responsiveness of tendon cells to stimuli associated with aging, comprising as active ingredients one or more ingredients selected from the group consisting of an extract of Geranium robertianum L., an extract of Sophora umbellata, an extract of Sanguisorba officinalis, and royal jelly.

[0024] In a preferred embodiment of the invention, the stimulus is applied mechanically or electrically.

[0025] A preferred form of the present invention is administered to a subject in conjunction with a stimulus.

[0026] A preferred embodiment of the present invention is used to suppress a decrease in the effect of improving changes in facial structure and / or mechanical function caused by stimulation of tendon cells associated with aging. Effect of the Invention

[0027] According to the present invention, it is possible to search for an ingredient that is effective in improving subcutaneous tissue structure based on a new mechanism of action in which the expression level of the Piezo gene is enhanced to improve the structural and functional changes of the face associated with aging. Furthermore, according to the present invention, it is possible to provide an ingredient that is effective in improving the structural and functional changes of the face associated with aging. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0028] The present invention will now be described. <1> A screening method using the expression level of the Piezo gene as an index, and <2> Agents related to increased expression of the Piezo gene are categorized and explained in detail.

[0029] <1> Screening method using the expression level of the Piezo gene as an index The screening method according to the present invention will now be described in detail. Here, screening includes searching for a target improving component or a candidate thereof.

[0030] There are two Piezo genes: Piezo1 and Piezo2. The screening method of the present invention preferably uses the expression level of the Piezo1 gene in cells as an index, and more preferably uses the expression level of the Piezo1 gene in tendon cells as an index.

[0031] The screening method of the present invention includes adding a test substance to a cell culture system and measuring the expression level of the Piezo gene in the cells. Specifically, when the expression level of the Piezo gene in the cells cultured with the test substance is higher than that in the cells cultured without the test substance, the test substance can be determined as a candidate for an improving component. More preferably, when the expression level of the Piezo gene is more than 1.5 times that of the cells cultured without the addition of the test substance, the test substance is selected as a candidate for the improving component of the present invention. By adopting such a form, a more effective improving component can be screened.

[0032] The expression level of the Piezo gene can be measured by standard methods such as immunochemical analysis, such as ELISA, Western blotting, and immunostaining, or mRNA measurement. For example, the expression level of a gene encoding the expression of a Piezo protein is measured by performing PCR using a DNA fragment having a sequence that specifically binds to the sequence of the gene as a primer, and quantitatively detecting mRNA. Note that the gene sequence encoding the expression of the Piezo protein is publicly available, so that a person skilled in the art can appropriately design a primer. Alternatively, a commercially available primer may be purchased as appropriate.

[0033] When carrying out the screening method of the present invention, the cells used are not particularly limited, but tendon cells are preferably used. A medium commonly used by those skilled in the art can be used for culturing the cells. Furthermore, the culture conditions for culturing the cells can be appropriately set depending on the cells to be used, etc.

[0034] The substance to be tested in the screening method of the present invention may be any of a pure substance, an extract derived from a living organism, or a mixture thereof, etc. The extract derived from a living organism is a general term not only for the extract itself derived from an animal or plant, but also for a fraction of the extract, a purified fraction, and a product obtained by removing the solvent from the extract or fraction or the purified product, and the extract derived from a plant may be an extract using a wild-growing or grown plant, an extract sold as a raw material for a herbal medicine, or a commercially available extract.

[0035] As mentioned above, the expression level of the Piezo gene decreases with age. If a component has an effect of enhancing the expression level of the Piezo gene, it can suppress this decrease in the expression level of the Piezo gene associated with age. In other words, by using the expression level of the Piezo gene in cells as an index, it is possible to screen for components that can be used to improve the age-related decrease in the expression level of the Piezo gene. This screening method makes it possible to screen for components that bring the expression level of the Piezo gene, which decreases with age, closer to that of a young person.

[0036] As mentioned above, the decrease in the expression level of the Piezo gene with age is a factor in the deterioration of tendon structure and, in turn, in the changes in facial structure and mechanical function. Based on this knowledge, a component that has the effect of increasing the expression level of the Piezo gene can improve the changes in facial structure and mechanical function that occur with age. In other words, by using the expression level of the Piezo gene in cells as an index, it is possible to screen for components that improve age-related changes in facial structure and / or changes in mechanical function.

[0037] Here, the "age-related changes in facial structure and / or mechanical function" preferably refer to changes resulting from deterioration of tendons or structures supported by tendons with age.

[0038] Examples of structures supported by tendons include structures surrounding the tendon in the subcutaneous tissue. Examples include peritendine fascia, peritendine septum, peritendine retinaculum (Retinacula cutis), and peritendine ligament. For example, the Playsma auricular fascia is an example of a fascia surrounding a tendon. Examples of septa around the tendon include the superior temporal septum, inferior temporal septum, and mandibular septum. Examples of ligaments include retinal ligaments and retaining ligaments. Further examples of cutaneous ligaments include the buccal cutaneous ligament and the masseteric cutaneous ligament. Examples of supporting ligaments include the orbital ligament, the orbitobuccal ligament, the maxillary ligament, and the mandibular ligament. In particular, the present invention is particularly effective in screening for components that improve age-related changes in facial structure and / or changes in mechanical function caused by deterioration of the retinaculum and ligaments.

[0039] Specific examples of "changes in facial structure due to aging" include facial sagging, wrinkles, and unevenness of the facial surface. Here, among "facial wrinkles," wrinkles that are particularly suitable as targets for improvement in the present invention are those caused by deterioration of facial tendons or structures supported by tendons. Specific examples include nasolabial folds, nasolabial folds, marionette lines, etc. Furthermore, among the "facial surface irregularities," those that are particularly suitable for improvement in accordance with the present invention are facial skin surface irregularities caused by deterioration of facial tendons or structures supported by the tendons.

[0040] "Changes in facial mechanical function with aging" include a decrease in skin elasticity.

[0041] As described above, the level of increased expression of the Piezo gene caused by the response of tendon cells to stimulation decreases with age. A component that has the effect of increasing the expression level of the Piezo gene can suppress this decrease in the response of tendon cells to stimulation with age. In other words, by using the expression level of the Piezo gene in cells as an indicator, it is possible to screen for components that improve the decline in stimulus responsiveness of tendon cells that occurs with aging.

[0042] As mentioned above, increased expression of the Piezo gene induces an increase in Mkx, leading to tendon strengthening. In other words, increased expression of the Piezo gene by stimulating tendon cells leads to tendon strengthening through an increase in Mkx, and ultimately to improvements in changes in facial structure and mechanical function. Given that the degree of increased expression of the Piezo gene caused by the stimulus response of tendon cells decreases with age, it can be said that the effect of stimulating tendon cells in improving changes in facial structure and mechanical function decreases with age. In light of the above, by using the expression level of the Piezo gene in cells as an indicator, it is possible to screen for components that suppress the age-related decline in the improving effect on facial structural changes and / or mechanical function changes induced by stimulation of tendon cells.

[0043] <2> Agents related to increased expression of the Piezo gene The present invention contains, as active ingredients, one or more ingredients selected from the group consisting of an extract of Geranium robertianum L. of the Geraniaceae family, an extract of Sanguisorba officinalis of the Rosaceae family, an extract of Sophora japonica, and royal jelly.

[0044] As described later in the Examples, each of the above components alone has the effect of increasing the expression of the Piezo gene. Therefore, the agent of the present invention may be in a form containing each component alone, or in a form containing two or more components in combination.

[0045] The agent preferably contains one or more of the following active ingredients: mulberry bark extract, sanguisorba officinalis extract, and royal jelly. Such an agent has an excellent effect of enhancing the expression of the Piezo gene.

[0046] When two or more ingredients are combined, the method of combination is not particularly limited, but suitable examples include a combination of Geranium phillyraeoides extract and Sophora japonica extract, and a combination of Sanguinea oleander extract and royal jelly.

[0047] When two components are combined, their content ratio (dry mass ratio) is not particularly limited, but is preferably 2:1 to 1:2, and particularly preferably 1.5:1 to 1:1.5.

[0048] The extracts of Geranium, Sophora gracilis and Sanguinea oleracea refer collectively to not only the primary extracts but also fractions of these extracts, purified fractions, and products from which the solvent has been removed from the extracts, fractions and purified products.

[0049] Examples of extracts of Geranium gracilis and Sanguineum gracilis include extracts using wild or cultivated plants, extracts sold as raw materials for herbal medicines, and commercially available extracts. When extracting the above-mentioned extract, in addition to using the whole plant, parts of the plant, such as the plant body, above-ground parts, rhizomes, trunks, leaves, stems, inflorescences, and flower buds, can be used for the extraction operation, but it is preferable to crush or chop these in advance to improve the extraction efficiency. Furthermore, when extracting the above-mentioned extract, in addition to using the whole plant, parts of the plant, such as the plant body, above-ground parts, rhizomes, trunks, leaves, stems, inflorescences, and flower buds, can be used in the extraction operation, but it is preferable to crush or chop these in advance to improve the extraction efficiency.

[0050] The extract of Morus alba may be prepared by using Morus alba as a raw material by a method well known to those skilled in the art, or a commercially available product may be used. The mulberry bark for extracting the mulberry bark extract may be a commercially available herbal medicine raw material. The mulberry bark is preferably the root bark of a plant of the Moraceae family, more preferably the root bark of Morus alba Linné or the root bark of Morus bombycis Koidzumi. Also, the mulberry tree may be produced by using the root bark as a base and drying a part or the whole of the root bark.

[0051] Suitable examples of extraction solvents used to prepare extracts of Geranium, Sophora gracilis and Sanguinea japonica include one or more selected from the group consisting of water, alcohols such as ethanol, isopropyl alcohol and butanol, polyhydric alcohols such as 1,3-butylene glycol, 1,3-butanediol and polypropylene glycol, ketones such as acetone and methyl ethyl ketone, and ethers such as diethyl ether and tetrahydrofuran.

[0052] Specific examples of the extraction method for the above extract include a method in which 1 to 30 parts by mass of a solvent is added per 1 mass of the part of the plant body or the dried part used for extraction, followed by immersion for several days at room temperature or several hours at a temperature near the boiling point, and then cooling to room temperature, after which insoluble matter and / or the solvent are removed as desired, and fractionation and purification is performed by column chromatography or the like, but the extraction method is not limited thereto.

[0053] Royal jelly is usually commercially available, and an extract of honeybee secretion and / or a purified product thereof may be used. Alternatively, a royal jelly extract, which is an extract of royal jelly, may be used. The extract may be a commercially available product. Alternatively, the extract may be extracted from royal jelly, which is a raw material, by a method well known to those skilled in the art. For example, it may be obtained by extracting a substance secreted from secretory glands in the head or the like of the European honeybee (Apis mellifera Linnaeus) or the Asian honeybee (Apis cerana Fabricius) with water, ethanol, 1,3-butylene glycol, or a mixture thereof.

[0054] The agent of the present invention is preferably in the form of an external preparation or an oral preparation by appropriately combining with any ingredient used in formulation. Examples of external preparations include cosmetics, quasi-drugs, and skin external medicines. The dosage form is not particularly limited. In relation to the purpose of promoting the expression of the Piezo gene, it is preferable to use the external preparation in the form of a cosmetic that can be used continuously. Examples of the external preparation include lotion, beauty essence, milky lotion, cream, gel, and sun care products.

[0055] The content (dry mass) of each extract in the topical preparation is usually 0.00001 mass% or more, preferably 0.0001 mass% or more, more preferably 0.001 mass% or more, and particularly preferably 0.01 mass% or more, and is usually 10 mass% or less, preferably 1 mass% or less, more preferably 0.5 mass% or less, and particularly preferably 0.2 mass% or less. Furthermore, in the case of an external preparation containing a composite extract, the total content (dry mass) of the composite extract is usually 0.00001 mass% or more, preferably 0.0001 mass% or more, more preferably 0.001 mass% or more, and particularly preferably 0.01 mass% or more, and is usually 10 mass% or less, preferably 1 mass% or less, more preferably 0.5 mass% or less, and particularly preferably 0.3 mass% or less.

[0056] In addition, when the agent is to be administered orally, it is preferably in the form of a food composition containing the agent of the present invention. More specifically, it is preferably in the form of a supplement having a dosage form such as a general food, tablet, granule, or drink.

[0057] In the case of oral preparations, the amount to be taken per dose is usually 0.1 mg or more, preferably 1 mg or more, more preferably 10 mg or more, in terms of the dry mass of each extract, depending on the dosage form, and is usually 2000 mg or less, preferably 1000 mg or less, more preferably 500 mg or less. In the case of an oral preparation containing a complex extract, the total intake amount per dose is usually 0.1 mg or more, preferably 1 mg or more, more preferably 10 mg or more, in terms of the dry mass of the complex extract, depending on the dosage form, and is usually 2000 mg or less, preferably 1000 mg or less, more preferably 500 mg or less.

[0058] When the agent of the present invention is in the form of a cosmetic preparation, it is possible to blend a wide variety of ingredients that are usually used in cosmetic preparations, and there are no limitations on the formulation form or use.

[0059] The agent of the present invention, which contains the above-mentioned components as active ingredients, can be used to enhance the expression level of the Piezo gene. According to the present invention, the expression level of the Piezo gene, which decreases with age, can be enhanced to bring it closer to a young state. The agent of the present invention is preferably used to enhance the expression of the Piezo gene in tendon cells.

[0060] As described above, the expression level of Mkx is increased by increasing the expression level of the Piezo gene. When the expression level of Mkx is increased, the tendon structure is strengthened. Therefore, the agent of the present invention can be used to improve the changes in facial structure and / or mechanical function associated with aging. More specifically, the agent of the present invention can be used to improve the changes in facial structure and / or mechanical function caused by the deterioration of tendon structure associated with aging. The agent of the present invention is particularly effective when used for the purposes of improving facial sagging and wrinkles that accompany aging, improving facial surface irregularities, and preventing a decrease in skin elasticity. The explanation of the above-mentioned changes in facial structure and / or mechanical function is given in the above <1> The description of the screening method can be used.

[0061] As described above, the effect of enhancing the expression level of the Piezo gene due to the stimulus response of tendon cells decreases with age. The agent of the present invention, which has the effect of enhancing the expression level of the Piezo gene, can be used to improve the decrease in the stimulus response of tendon cells associated with age. According to the present invention, the expression level of the Piezo gene, which is caused by the response of tendon cells to stimulation and which declines with age, can be brought closer to the state of a young person.

[0062] As mentioned above, increased expression of the Piezo gene induces an increase in Mkx, leading to tendon strengthening. In other words, increased expression of the Piezo gene by stimulating tendon cells leads to tendon strengthening through an increase in Mkx, and ultimately to improvements in changes in facial structure and mechanical function. Given that the degree of increased expression of the Piezo gene caused by the stimulus response of tendon cells decreases with age, it can be said that the effect of stimulating tendon cells in improving changes in facial structure and mechanical function decreases with age. In light of the above, the agent of the present invention, which has the effect of enhancing the expression of the Piezo gene, can be used to suppress the age-related decline in the effect of improving the changes in facial structure and / or mechanical function caused by stimulation of tendon cells.

[0063] The agent of the present invention can be administered to a subject when applying stimulation to the subject. In the present invention, the stimulus is preferably a stimulus applied mechanically or electrically to tendon cells. The mechanically applied stimuli include a stretching stimulus, a contracting stimulus, a compressive stimulus, and a shear stress. Preferably, the stretch stimulus is one that physically stretches tendon cells. The mechanical stimulation applied to the tendon cells may be applied from above the epidermis, for example, by massage using fingers or a beauty device.

[0064] The electrically applied stimuli also include mechanical stimuli that are indirectly applied to tendon cells. The mechanical stimuli indirectly applied to the tendon cells include stretch stimuli, contraction stimuli, compression stimuli, and shear stress. Preferably, the stretch stimuli is applied indirectly to the tendon cells by contracting the muscle with electrical stimulation. The electrical stimulation applied to the tendon cells may be applied from above the epidermis. Examples of the treatment include beauty devices and medical devices. As the above-mentioned devices, a beauty device that utilizes electrical stimulation to muscles, such as EMS, is preferably used.

[0065] When the agent of the present invention is administered to a subject when stimulating the subject, the administration form is preferably a topical application. It is preferable to directly apply the agent of the present invention to the skin of the subject and to stimulate the applied skin. Preferably, the agent of the present invention is applied to the skin of a subject and then the skin is stimulated. By using the above method, the agent of the present invention can be more effectively penetrated into the skin, thereby improving the decrease in responsiveness of tendon cells to stimuli that occurs with aging. The agent of the present invention may be directly injected into the skin, or may be penetrated deep into the skin by an electric current, for example, by electroporation.

[0066] The agent of the present invention is preferably administered to aged individuals in which the expression level of the Piezo gene is reduced compared to the younger state. In addition, administration to aged individuals is suitable in which the level of enhanced expression of the Piezo gene caused by the stimulus response of tendon cells is reduced compared to younger individuals. Examples of age groups of elderly people suitable for administration of the agent of the present invention include those in their 30s, 40s, and particularly those in their 50s and 60s. Note that the agent of the present invention is also effective for people in other age groups as long as the level of enhanced expression of the Piezo gene is reduced. EXAMPLES

[0067] <Test Example 1> Age-related changes in Piezo1 expression in tenocytes The study used tendon cells from donated bodies aged 59, 87, and 96 years (hereafter, the tendon cells used will be referred to as 59 yo, 87 yo, and 96 yo). Tendon cells (59 yo, 87 yo, and 96 yo) were seeded on culture plates to semi-confluence in DEN-1 medium (ZenBio). After adhesion, they were cultured for 24 hours, and RNA was extracted. Piezo1 gene expression was evaluated using real-time RT-PCR. The expression level of Piezo1 was normalized by the expression level of GAPDH as a housekeeping gene.

[0068] (result) The gene expression ratios of Piezo1 in tendon cells (59 yo, 87 yo, and 96 yo) are shown in Table 1. Compared with tenocytes (59 yo), the Piezo1 expression ratio in tenocytes (87 yo and 96 yo) significantly decreased with age. In addition, the Piezo1 expression ratio in tendon cells (96 yo) compared with that in tendon cells (87 yo) also significantly decreased with age. In other words, Piezo1 expression decreases with age. [Table 1]

[0069] <Test Example 2> Age-related changes in response to stretch stimuli in tenocytes Tendon cells (59 yo, 87 yo, and 96 yo) were seeded in a stretch chamber in DEN-1 medium (ZenBio) to reach semi-confluence. After adhesion, the cells were stretched for 6 hours at 5% stretch with a frequency of 30 cycles per minute to achieve 100-105% tenocyte proliferation. RNA was then harvested. Piezo1 gene expression was evaluated using real-time RT-PCR. The expression level of Piezo1 was normalized by the expression level of GAPDH as a housekeeping gene.

[0070] (result) Table 2 shows the gene expression ratios of Piezo1 in tendon cells (59 yo, 87 yo, and 96 yo) subjected to stretch stimulation. The increase in Piezo1 expression in tendon cells induced by stretch stimulation decreased with age. In other words, the responsiveness of Piezo1 expression to stretch stimulation decreases with age. [Table 2]

[0071] <Test Example 3> Extract that enhances Piezo1 expression in tenocytes Tendon cells (87 yo) were seeded on a culture plate in DEN-1 medium (ZenBio) until they were semi-confluent. After adhesion, various active ingredient extracts were added and the cells were cultured for 24 hours, and RNA was collected. Piezo1 gene expression was evaluated using real-time RT-PCR. The expression level of Piezo1 was corrected with the expression level of GAPDH as a housekeeping gene. As a control, the gene expression level of Piezo1 cultured without the addition of each active ingredient extract was compared. The various active ingredient extracts used above were the following extracts: - Geranium extract (manufactured by Ichimaru Falcos) ·Morus alba root bark extract (Maruzen Pharmaceuticals) Sanguinea oleifera extract (Maruzen Pharmaceuticals) Royal jelly extract (Kukida Pharmaceutical Co., Ltd.)

[0072] (result) Table 3 shows the gene expression ratio of Piezo1 in tendon cells (87 yo) cultured with various active ingredient extracts. Compared to the control, the gene expression ratio of Piezo1 was increased in tendon cells (87 yo) cultured with the addition of each active ingredient extract. Furthermore, the gene expression ratio of Piezo1 in tendon cells (87 yo) was increased when each extract, which is an active ingredient of the present invention, was used alone, compared to the control. In particular, significant enhancement was observed with 0.1% by mass of Sophora umbellata extract, 0.1% by mass of Sanguisorba officinalis extract, and 0.1% by mass of royal jelly extract.

[0073] Furthermore, in the case of the composite extract, the gene expression ratio of Piezo1 was significantly increased in tendon cells (87 yo) cultured with the addition of 0.1% by mass of Geranium + 0.1% by mass of Sophora japonica extract, or 0.1% by mass of Sanguinea oleracea extract + 0.1% by mass of royal jelly extract. In other words, it can be said that Piezo1 expression, which declines with age, can be brought closer to a youthful state by the active ingredient extract of the present invention. [Table 3] [Industrial Applicability]

[0074] The present invention can be applied to the formulation design of cosmetics and supplements.

Claims

1. A screening method comprising selecting a component that improves age-related changes in facial structure and / or mechanical function using the expression level of the Piezo gene in cells as an index.

2. 2. The method of claim 1, wherein the age-related changes in the face are due to age-related deterioration of facial tendons or structures supported by the tendons.

3. The method for screening according to claim 1, wherein the facial changes associated with aging are at least one selected from the group consisting of facial sagging, facial wrinkles, facial surface irregularities, and reduced skin elasticity.

4. A screening method comprising selecting a component used to improve a decrease in the expression level of the Piezo gene associated with aging, using the expression level of the Piezo gene in cells as an index.

5. A screening method comprising selecting a component that improves the age-related decrease in stimulus responsiveness of tendon cells using the expression level of the Piezo gene in the cells as an indicator.

6. The screening method according to any one of claims 1 to 5, characterized in that the expression level of the Piezo gene in tendon cells is used as an indicator.

7. An agent for enhancing the expression level of a Piezo gene, comprising one or more active ingredients selected from the group consisting of an extract of Geranium robertianum L., an extract of Sophora japonica, an extract of Sanguisorba officinalis, and royal jelly.

8. The agent according to claim 7, which is used for enhancing the expression level of the Piezo gene in tendon cells.

9. The agent according to claim 7, which is used to improve age-related changes in facial structure and / or mechanical function.

10. An agent for improving age-related changes in facial structure and / or mechanical function, comprising one or more active ingredients selected from the group consisting of an extract of Geranium robertianum L., an extract of Sophora japonica, an extract of Sanguisorba officinalis, and royal jelly.

11. 11. The method of claim 9 or 10, wherein the age-related changes in the face are due to age-related deterioration of facial tendons or structures supported by the tendons.

12. The agent according to claim 9 or 10, wherein the age-related changes in the face are at least one selected from the group consisting of age-related facial sagging, facial wrinkles, facial surface irregularities, and decreased skin elasticity.

13. The agent according to claim 7, which is used to improve the decline in stimulus responsiveness of tendon cells associated with aging.

14. An agent for improving the decrease in responsiveness of tendon cells to stimuli associated with aging, comprising one or more active ingredients selected from the group consisting of an extract of Geranium robertianum L., an extract of Sophora japonica, an extract of Sanguisorba officinalis, and royal jelly.

15. The agent according to claim 13 or 14, wherein the stimulus is applied mechanically or electrically.

16. The agent according to claim 13 or 14, which is administered to a subject together with a stimulus.

17. The agent according to claim 13 or 14, which is used to suppress a decrease in the effect of improving changes in facial structure and / or mechanical function caused by stimulation of tendon cells associated with aging.

Citation Information

Patent Citations

  • Method for screening components that improve subcutaneous tissue structure

    JP6993076B2

  • Skin retinaculum improvement agent

    JP7190248B2